Gilead Sciences, Inc. (GILD) announced the FDA approved a new low-dose tablet dosage form of Biktarvy for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy. The company said this approval expands the indication for Biktarvy to include younger children living with HIV-1 infection.

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

Gilead Sciences, Inc. (GILD) announced the FDA approved a new low-dose tablet dosage form of Biktarvy for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy. The company said this approval expands the indication for Biktarvy to include younger children living with HIV-1 infection.

RTTNews | Oct 18, 2021 07:47AM EDT

07:47 Monday, October 18, 2021 (RTTNews.com) - Gilead Sciences, Inc. (GILD) announced the FDA approved a new low-dose tablet dosage form of Biktarvy for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy. The company said this approval expands the indication for Biktarvy to include younger children living with HIV-1 infection.

Merdad Parsey, Chief Medical Officer, Gilead Sciences, said: "The sNDA approval is an important step in fulfilling Gilead's commitment to a goal of bringing pediatric formulations of Biktarvy to children living with HIV around the world."

Read the original article on RTTNews ( https://www.rttnews.com/3233248/gilead-sciences-fda-approves-low-dose-tablet-dosage-form-of-biktarvy-for-pediatric-patients.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved